SK Chemicals285130.KS
本公司簡介的中文翻譯準備中。以下為英文原文。
關於SK Chemicals
SK Chemicals operates two distinct businesses under one roof: green materials and pharmaceuticals. The materials arm produces copolyester resins, a BPA-free alternative to conventional plastics used in cosmetics packaging and household goods, and has pushed into chemically recycled plastics. The life-science arm develops and sells pharmaceutical products, and the company is the controlling shareholder of vaccine maker SK Bioscience. SK Chemicals sits within SK Discovery, a holding structure separate from the main SK Inc. lineage of the wider SK Group. Earnings blend specialty-chemical margins with pharmaceutical income and consolidated vaccine results.
The controlling stake in listed subsidiary SK Bioscience is central to how foreign investors value the shares, creating a holding-company dynamic in which the parent often trades below the appraised worth of its parts. Copolyester demand links the company to global consumer-packaging trends and to regulatory momentum against conventional plastics, a structural tailwind that also invites competition. Its position within SK Discovery, rather than under the main SK holding company, matters for governance analysis. Currency movements affect the materials business, which exports a meaningful share of its output.
The company began in 1969 as Sunkyong Fibers, a polyester producer that anchored the early manufacturing ambitions of the Sunkyong group, later SK. It adopted the SK Chemicals name in 1998 as it shifted from textiles toward specialty chemicals and life science, and in 1999 it won approval for Sunpla, recognized as South Korea's first domestically developed new drug. A December 2017 reorganization divided the old company into SK Discovery, a holding entity, and today's operating SK Chemicals, which relisted in early 2018. The vaccine unit was carved out separately in 2018 to create SK Bioscience.
Revenue rests on two engines with different mechanics. The green-materials arm sells copolyester resins under brands such as ECOZEN and SKYGREEN, earning specialty margins from customers in cosmetics packaging, consumer goods, and appliances who pay up for clarity, durability, and BPA-free credentials; recycled-content grades extend that franchise. The pharmaceutical arm generates product sales from its own portfolio, including patch-based pain treatments and circulation-improvement drugs, plus consolidated results from SK Bioscience. Competitive position in copolyester is unusually strong because only a handful of producers worldwide master the chemistry, while the pharma unit competes in crowded domestic therapeutic markets.
公司簡介由LineVest編輯部撰寫。屬新聞報導，非投資建議。 委託撰寫SK Chemicals的DART完整報告 →
SK Chemicals相關報導
尚無SK Chemicals相關文章 — LineVest每日發布韓國市場新聞，SK Chemicals的新報導將自動顯示於此。
瀏覽最新韓國市場新聞 →常見問題
What does SK Chemicals do?
SK Chemicals runs two businesses: a green-materials division producing copolyester resins and recycled plastics used in packaging and consumer products, and a pharmaceutical division selling its own medicines in Korea. It is also the controlling shareholder of vaccine developer SK Bioscience, whose results are consolidated into the company's accounts.
Who controls SK Chemicals?
SK Discovery, a listed intermediate holding company led by Vice Chairman Chey Chang-won of the founding family, controls SK Chemicals. This lineage sits apart from SK Inc., the main SK Group holding company, though both share the SK name and heritage. Institutional and retail shareholders hold the remaining shares.
How can foreign investors get exposure to SK Chemicals?
Shares of SK Chemicals trade on the KOSPI board of the Korea Exchange under ticker 285130. Foreign investors can trade them through brokerages offering Korean equity access after standard registration. Korea-focused index funds also carry the name, offering indirect exposure for those who prefer not to trade Seoul-listed shares directly.
答覆為一般資訊之編輯摘要，非投資建議。
深入標題背後
您剛讀到發生了什麼。接下來，讀懂它意味著什麼。
每天早晨的韓國市場 — 免費
LineVest Daily在首爾開盤前送達您的信箱：KOSPI與KOSDAQ關鍵報導、財報、披露與外資流向 — 以簡明英文呈現。免費，無需信用卡。
SK Chemicals完整報告
我們完整閱讀SK Chemicals的最新DART披露 — K-IFRS財務、公司治理，以及對股價的意義。3小時內PDF送達您的信箱。
$12 · 單次
獲取SK Chemicals報告基於DART原始披露的獨立新聞報導 — 非投資建議。與任何券商無關。